Overview

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Status:
RECRUITING

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

aflutinib
Bevacizumab
Pemetrexed